1. Home
  2. GLPG vs LCII Comparison

GLPG vs LCII Comparison

Compare GLPG & LCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLPG
  • LCII
  • Stock Information
  • Founded
  • GLPG 1999
  • LCII 1956
  • Country
  • GLPG Belgium
  • LCII United States
  • Employees
  • GLPG N/A
  • LCII N/A
  • Industry
  • GLPG Biotechnology: Pharmaceutical Preparations
  • LCII Auto Parts:O.E.M.
  • Sector
  • GLPG Health Care
  • LCII Consumer Discretionary
  • Exchange
  • GLPG Nasdaq
  • LCII Nasdaq
  • Market Cap
  • GLPG 2.1B
  • LCII 2.5B
  • IPO Year
  • GLPG 2005
  • LCII N/A
  • Fundamental
  • Price
  • GLPG $32.02
  • LCII $100.32
  • Analyst Decision
  • GLPG Sell
  • LCII Hold
  • Analyst Count
  • GLPG 4
  • LCII 4
  • Target Price
  • GLPG $25.33
  • LCII $89.33
  • AVG Volume (30 Days)
  • GLPG 198.2K
  • LCII 233.5K
  • Earning Date
  • GLPG 10-29-2025
  • LCII 11-06-2025
  • Dividend Yield
  • GLPG N/A
  • LCII 4.58%
  • EPS Growth
  • GLPG N/A
  • LCII 25.42
  • EPS
  • GLPG N/A
  • LCII 5.97
  • Revenue
  • GLPG $323,674,692.00
  • LCII $3,871,475,000.00
  • Revenue This Year
  • GLPG N/A
  • LCII $7.69
  • Revenue Next Year
  • GLPG N/A
  • LCII $3.72
  • P/E Ratio
  • GLPG N/A
  • LCII $16.80
  • Revenue Growth
  • GLPG 5.43
  • LCII 1.36
  • 52 Week Low
  • GLPG $22.36
  • LCII $72.31
  • 52 Week High
  • GLPG $33.86
  • LCII $129.38
  • Technical
  • Relative Strength Index (RSI)
  • GLPG 49.28
  • LCII 44.64
  • Support Level
  • GLPG $30.88
  • LCII $101.02
  • Resistance Level
  • GLPG $33.63
  • LCII $104.10
  • Average True Range (ATR)
  • GLPG 0.69
  • LCII 2.38
  • MACD
  • GLPG -0.02
  • LCII -0.76
  • Stochastic Oscillator
  • GLPG 41.45
  • LCII 0.80

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About LCII LCI Industries

LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.

Share on Social Networks: